{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Hahn NM"],"funding":["NCI","NCI NIH HHS"],"pagination":["3003-3011"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC5462889"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["23(12)"],"pubmed_abstract":["<b>Purpose:</b> To assess the clinical and pharmacodynamic activity of dovitinib in a treatment-resistant, molecularly enriched non-muscle-invasive urothelial carcinoma of the bladder (NMIUC) population.<b>Experimental Design:</b> A multi-site pilot phase II trial was conducted. Key eligibility criteria included the following: Bacillus Calmette-Guerin (BCG)-unresponsive NMIUC (<u>></u>2 prior intravesical regimens) with increased phosphorylated FGFR3 (pFGFR3) expression by centrally analyzed immunohistochemistry (IHC+) or <i>FGFR3</i> mutations (Mut+) assessed in a CLIA-licensed laboratory. Patients received oral dovitinib 500 mg daily (5 days on/2 days off). The primary endpoint was 6-month TURBT-confirmed complete response (CR) rate.<b>Results:</b> Between 11/2013 and 10/2014, 13 patient"],"journal":["Clinical cancer research : an official journal of the American Association for Cancer Research"],"pubmed_title":["A Phase II Trial of Dovitinib in BCG-Unresponsive Urothelial Carcinoma with <i>FGFR3</i> Mutations or Overexpression: Hoosier Cancer Research Network Trial HCRN 12-157."],"pmcid":["PMC5462889"],"funding_grant_id":["P30 CA006973","P30CA006973","P30 CA082709"],"pubmed_authors":["Masterson TA","Gardner TA","Greenberg RE","Hahn NM","Liu Z","Baras A","Jones DR","Ross AE","Loman RL","Cheng L","Geynisman DM","Chapman C","Sandusky GE","Tsongalis GJ","Albany C","Gallagher T","Bihrle R","Breen T","Foster RS","Netto GJ","Moore ML","Bivalacqua TJ","McElyea K","Koch MO","Turner SA","De Abreu FB","Plimack ER","Park JC","Reed A"],"additional_accession":[]},"is_claimable":false,"name":"A Phase II Trial of Dovitinib in BCG-Unresponsive Urothelial Carcinoma with <i>FGFR3</i> Mutations or Overexpression: Hoosier Cancer Research Network Trial HCRN 12-157.","description":"<b>Purpose:</b> To assess the clinical and pharmacodynamic activity of dovitinib in a treatment-resistant, molecularly enriched non-muscle-invasive urothelial carcinoma of the bladder (NMIUC) population.<b>Experimental Design:</b> A multi-site pilot phase II trial was conducted. Key eligibility criteria included the following: Bacillus Calmette-Guerin (BCG)-unresponsive NMIUC (<u>></u>2 prior intravesical regimens) with increased phosphorylated FGFR3 (pFGFR3) expression by centrally analyzed immunohistochemistry (IHC+) or <i>FGFR3</i> mutations (Mut+) assessed in a CLIA-licensed laboratory. Patients received oral dovitinib 500 mg daily (5 days on/2 days off). The primary endpoint was 6-month TURBT-confirmed complete response (CR) rate.<b>Results:</b> Between 11/2013 and 10/2014, 13 patient","dates":{"release":"2017-01-01T00:00:00Z","publication":"2017 Jun","modification":"2026-05-04T21:00:44.901Z","creation":"2019-03-26T23:41:24Z"},"accession":"S-EPMC5462889","cross_references":{"pubmed":["27932416"],"doi":["10.1158/1078-0432.CCR-16-2267","10.1158/1078-0432.ccr-16-2267"]}}